Brown Advisory Inc. raised its holdings in Laboratory Corp. of America Holdings (NYSE:LH) by 15.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 49,345 shares of the medical research company’s stock after acquiring an additional 6,720 shares during the quarter. Brown Advisory Inc.’s holdings in Laboratory Corp. of America were worth $6,234,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Victory Capital Management Inc. raised its position in Laboratory Corp. of America by 20.8% in the 3rd quarter. Victory Capital Management Inc. now owns 55,393 shares of the medical research company’s stock valued at $9,620,000 after purchasing an additional 9,525 shares in the last quarter. Private Advisor Group LLC raised its position in Laboratory Corp. of America by 63.6% in the 3rd quarter. Private Advisor Group LLC now owns 5,938 shares of the medical research company’s stock valued at $1,031,000 after purchasing an additional 2,309 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its position in Laboratory Corp. of America by 2.3% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 328,728 shares of the medical research company’s stock valued at $57,093,000 after purchasing an additional 7,469 shares in the last quarter. JPMorgan Chase & Co. raised its position in Laboratory Corp. of America by 14.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,645,798 shares of the medical research company’s stock valued at $285,845,000 after purchasing an additional 213,849 shares in the last quarter. Finally, Toronto Dominion Bank raised its position in Laboratory Corp. of America by 0.8% in the 3rd quarter. Toronto Dominion Bank now owns 66,269 shares of the medical research company’s stock valued at $11,506,000 after purchasing an additional 544 shares in the last quarter. 88.80% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have issued reports on the company. ValuEngine raised Laboratory Corp. of America from a “sell” rating to a “hold” rating in a research report on Monday, March 11th. Credit Suisse Group increased their price target on Laboratory Corp. of America from $160.00 to $164.00 and gave the company an “outperform” rating in a research report on Wednesday, February 27th. Morgan Stanley set a $175.00 price target on Laboratory Corp. of America and gave the company a “buy” rating in a research report on Friday, February 22nd. Zacks Investment Research raised Laboratory Corp. of America from a “sell” rating to a “hold” rating in a research report on Monday, February 11th. Finally, UBS Group set a $178.00 price objective on Laboratory Corp. of America and gave the company a “buy” rating in a report on Friday, February 8th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $176.07.

LH opened at $154.36 on Friday. Laboratory Corp. of America Holdings has a one year low of $119.38 and a one year high of $190.35. The stock has a market capitalization of $15.07 billion, a PE ratio of 14.01, a price-to-earnings-growth ratio of 1.72 and a beta of 1.15. The company has a current ratio of 1.51, a quick ratio of 1.38 and a debt-to-equity ratio of 0.87.

Laboratory Corp. of America (NYSE:LH) last released its quarterly earnings data on Thursday, February 7th. The medical research company reported $2.52 EPS for the quarter, beating analysts’ consensus estimates of $2.48 by $0.04. Laboratory Corp. of America had a return on equity of 17.05% and a net margin of 8.43%. The business had revenue of $2.79 billion for the quarter, compared to the consensus estimate of $2.78 billion. During the same quarter in the prior year, the business posted $2.45 EPS. The business’s revenue for the quarter was up 1.6% on a year-over-year basis. On average, research analysts expect that Laboratory Corp. of America Holdings will post 11.22 earnings per share for the current year.

In related news, Director R Sanders Williams sold 1,038 shares of the firm’s stock in a transaction that occurred on Wednesday, February 13th. The stock was sold at an average price of $147.00, for a total transaction of $152,586.00. Following the transaction, the director now owns 8,924 shares in the company, valued at approximately $1,311,828. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.73% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Brown Advisory Inc. Acquires 6,720 Shares of Laboratory Corp. of America Holdings (LH)” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://theolympiareport.com/2019/03/17/brown-advisory-inc-acquires-6720-shares-of-laboratory-corp-of-america-holdings-lh.html.

About Laboratory Corp. of America

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens.

Read More: Can systematic risk be avoided?

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corp. of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.